A Humanized Anti-DLL4 Antibody Promotes Dysfunctional Angiogenesis and Inhibits Breast Tumor Growth

Overview

Journal Sci Rep

Specialty Science

Date 2016 Jun 16

PMID 27301650

Citations 17

Authors

Xuelian Jia

Wenyi Wang

Zhuobin Xu

Shijing Wang

Tong Wang

Min Wang

Min Wu

Affiliations

Soon will be listed here.

Abstract

Blockage of Delta-like 4 (DLL4)-directed Notch signaling induces excessive tip cell formation and endothelial proliferation resulting in dysfunctional angiogenesis in tumors. MMGZ01, as a murine anti-human DLL4 monoclonal antibody, specifically binds to human DLL4 and blocks Notch pathway. Here, the structure of MMGZ01 variable fragment (Fv) was established and framework region (FR) residues which supported complementarily determining region (CDR) loop conformation were identified. Important residues interactions were also identified through docking MMGZ01 Fv with antigen epitope in DLL4. To humanize the murine antibody, we modified MMGZ01 Fv through CDR grafting and the reconstructed antibody (H3L2) maintained similar structure and binding affinity to parental MMGZ01 after back mutation of 12 canonical murine residues in the FRs. Meanwhile, H3L2 promoted human umbilical vein endothelial cell (HUVEC) proliferation through inhibiting DLL4-directed Notch pathway. Moreover, in MDA-MB-231-bearing nude mice, H3L2 induced dysfunctional angiogenesis and tumor cell apoptosis and showed superior anti-tumor activity. In conclusion, H3L2 is an ideal humanized antibody that inhibits tumor growth through targeting DLL4-Notch pathway and has attracting potentials for clinical applications.

Citing Articles

Oncogenic signaling-mediated regulation of chromatin during tumorigenesis.

Alam J, Huda M, Tackett A, Miah S Cancer Metastasis Rev. 2023; 42(2):409-425.

PMID: 37147457 PMC: 10348982. DOI: 10.1007/s10555-023-10104-3.

DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment.

Kumari M, Krishnamurthy P, Pinduprolu S, Sola P Adv Pharm Bull. 2021; 11(4):618-623.

PMID: 34888208 PMC: 8642801. DOI: 10.34172/apb.2021.070.

Mammary Development and Breast Cancer: a Notch Perspective.

Chen W, Wei W, Yu L, Ye Z, Huang F, Zhang L J Mammary Gland Biol Neoplasia. 2021; 26(3):309-320.

PMID: 34374886 PMC: 8566423. DOI: 10.1007/s10911-021-09496-1.

Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.

Allen F, Maillard I Front Cell Dev Biol. 2021; 9:649205.

PMID: 34124039 PMC: 8194077. DOI: 10.3389/fcell.2021.649205.

The complexity of tumour angiogenesis based on recently described molecules.

Wisniewska W, Kopka M, Siemiatkowska K, Fudalej M, Sobiborowicz A, Badowska-Kozakiewicz A Contemp Oncol (Pozn). 2021; 25(1):33-44.

PMID: 33911980 PMC: 8063899. DOI: 10.5114/wo.2021.105075.

References

Thurston G, Noguera-Troise I, Yancopoulos G . The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer. 2007; 7(5):327-31. DOI: 10.1038/nrc2130. View

Chen R, Li L, Weng Z . ZDOCK: an initial-stage protein-docking algorithm. Proteins. 2003; 52(1):80-7. DOI: 10.1002/prot.10389. View

Guerois R, Nielsen J, Serrano L . Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol. 2002; 320(2):369-87. DOI: 10.1016/S0022-2836(02)00442-4. View

Takebe N, Nguyen D, Yang S . Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2013; 141(2):140-9. PMC: 3982918. DOI: 10.1016/j.pharmthera.2013.09.005. View

Hellstrom M, Phng L, Hofmann J, Wallgard E, Coultas L, Lindblom P . Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature. 2007; 445(7129):776-80. DOI: 10.1038/nature05571. View

Kashmiri S, De Pascalis R, Gonzales N, Schlom J . SDR grafting--a new approach to antibody humanization. Methods. 2005; 36(1):25-34. DOI: 10.1016/j.ymeth.2005.01.003. View

Bruggemann M, Winter G, Waldmann H, Neuberger M . The immunogenicity of chimeric antibodies. J Exp Med. 1989; 170(6):2153-7. PMC: 2189553. DOI: 10.1084/jem.170.6.2153. View

Lovell S, Davis I, Arendall 3rd W, de Bakker P, Word J, Prisant M . Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins. 2003; 50(3):437-50. DOI: 10.1002/prot.10286. View

Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V . Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004; 167(2):215-21. PMC: 2172557. DOI: 10.1083/jcb.200406140. View

10.

Stephen C, Lane D . Mutant conformation of p53. Precise epitope mapping using a filamentous phage epitope library. J Mol Biol. 1992; 225(3):577-83. DOI: 10.1016/0022-2836(92)90386-x. View

11.

Morea V, Lesk A, Tramontano A . Antibody modeling: implications for engineering and design. Methods. 2000; 20(3):267-79. DOI: 10.1006/meth.1999.0921. View

12.

Scehnet J, Jiang W, Kumar S, Krasnoperov V, Trindade A, Benedito R . Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood. 2007; 109(11):4753-60. PMC: 1885521. DOI: 10.1182/blood-2006-12-063933. View

13.

Jones P, Dear P, Foote J, Neuberger M, Winter G . Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986; 321(6069):522-5. DOI: 10.1038/321522a0. View

14.

Xie W, Li D, Zhang J, Li Z, Acheampong D, He Y . Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2. Cancer Immunol Immunother. 2014; 63(9):877-88. PMC: 11028991. DOI: 10.1007/s00262-014-1560-9. View

15.

Presta L, Chen H, OConnor S, Chisholm V, Meng Y, Krummen L . Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20):4593-9. View

16.

Neuberger M, Williams G, Mitchell E, Jouhal S, Flanagan J, Rabbitts T . A hapten-specific chimaeric IgE antibody with human physiological effector function. Nature. 1985; 314(6008):268-70. DOI: 10.1038/314268a0. View

17.

Hirschi K, Rohovsky S, BECK L, Smith S, DAmore P . Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ Res. 1999; 84(3):298-305. DOI: 10.1161/01.res.84.3.298. View

18.

Hackett Jr J, Golden A, Brashear J, Robinson J, Rapp M, Klass M . Recombinant mouse-human chimeric antibodies as calibrators in immunoassays that measure antibodies to Toxoplasma gondii. J Clin Microbiol. 1998; 36(5):1277-84. PMC: 104814. DOI: 10.1128/JCM.36.5.1277-1284.1998. View

19.

Chiorean E, LoRusso P, Strother R, Diamond J, Younger A, Messersmith W . A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015; 21(12):2695-703. DOI: 10.1158/1078-0432.CCR-14-2797. View

20.

Shapiro A, Botha J, Pastore A, Lesk A . A method for multiple superposition of structures. Acta Crystallogr A. 1992; 48 ( Pt 1):11-4. DOI: 10.1107/s010876739100867x. View